Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

WAIT

Was quite skeptical because the accounting looked suspect. Now that Mr. Pattison has made his move, will be prepared to buy once there are some positive moves.

Wealthica Track your Stocks in your Watch List

PAST TOP PICK

Had expected a nice bounce had expected a nice bounce but the bad news kept coming. The stock is getting very cheap. (A past top pick Oct 9/03. Down 37.99/26.23%.)

PAST TOP PICK

(A past top pick Nov 20/03. Down 14%.) Only nibbled at $30.30, hoping for a drop to $23. But more at that time. Would still buy some at $23.50.

TOP PICK

Have written a lot of stuff off the balance sheet and it looks in good shape. Try to buy at $23.50.

WAIT

In a phase where you are trying to catch a falling knife. Needs a lot of base building between $23/24 over the next 3/4/5 months. If the stock can get above $30, it could go to $45.

BUY

They have a technology that works and Glaxosmithkline has just picked up the option to sell it out outside of North America starting in 2006.

DON'T BUY

Prefers other pharmaceuticals. Wait to see what the consequences will be regarding the accounting situation. Product is very good.

WEAK BUY

Just heard that Jim Pattison has taken a large position in the company. Feels that anything he goes into will be successful. It is speculative.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Waiting for an FCC investigation and once that's over with, the stock will start moving again. Could have further competition with some of their mainstream drugs.

WEAK BUY

Have had concerns with recent developments. Still likes the stock for the longer-term. Has decent earnings for 2004. A small position would be OK.

DON'T BUY

Too much uncertainty with accounting, management and delivery issues. Wait for stabilization as well as for the stock to start rising.

DON'T BUY

Pharmaceutical group has been weak relative to the market. This has been one of the weakest in this group.

DON'T BUY

Might be suitable for an aggressive trader. Too premature to be looking at this as an investment candidate. There's a lack of clarity.

WEAK BUY

Will be volatile until there is more clarity and credibility. Treat it as a trading stock.

DON'T BUY

There are a lot of investigations going on. Too much uncertainty. A speculative stock.

Showing 481 to 495 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)